Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease

Clinical Laboratory

Volumn 58, Issue 5-6, 2012, Pages 471-480

  Zakiyanov, Oskar ^a   Kalousová, Marta ^a   Kratochvilová, Markéta ^a   Kříha, Vítězslav ^b   Zima, Tomáš ^a   Tesař, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

Albumin; Anaemia; Chronic kidney disease; Matrix metalloproteinase 2; Pregnancy associated plasma protein A; Proteinuria

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GELATINASE A; HEMOGLOBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOCHEMISTRY; KIDNEY INJURY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PROTEINURIA;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROTEINURIA; SERUM ALBUMIN;

EID: 84863700796     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005;12:353-65. (Pubitemid 41376493)
2. Arthur MJ. Fibrosis and altered matrix degradation. Digestion 1998;59:376-80. (Pubitemid 28360696)
3. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 2000;11:574-81. (Pubitemid 30115088)
4. Singhal PC, Sagar S, Garg P. Simulated glomerular pressure modulates mesangial cell 72 kDa metalloproteinase activity. Connect Tissue Res 1996;33:257-63. (Pubitemid 3021575)
5. Akiyama K, Shikata K, Sugimoto H, et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997;95:115-28. (Pubitemid 27147557)
6. Baricos WH. Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Curr Opin Nephrol Hypertens 1995;4:365-8.
7. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292:F905-F911. (Pubitemid 46393417)
8. El-Nahas AM. Plasticity of kidney cells: role in kidney remodeling and scarring. Kidney Int 2003;64:1553-63.
9. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, the ugly. Circ Res 2002;90:251-62. (Pubitemid 34633925)
10. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006;366:243-8.
11. Endo T, Nakabayashi K, Sekiuchi M, Kuroda T, Soejima A, Yamada A. Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunochemical staining. Clin Exp Nephrol 2006;10:253-61. (Pubitemid 46012954)
12. Nagano M, Fukami K, Yamagishi S, et al. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol 2009;29:109-15.
13. Schindler AM, Bischof P. Histochemical localization of pregnancy-associated plasma protein A in fetal, infant, and adult organs and comparison between antisera. Gynecol Obstet Invest 1984;18:88-94. (Pubitemid 14053119)
14. Overgaard MT, Oxvig C, Christiansen M, et al. Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and non-reproductive tissues. Biol Reprod 1999;61:1083-89. (Pubitemid 29455648)
15. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a new marker of acute coronary syndromes. N Engl J Med 2001;245:1022-9.
16. Fialova L, Kalousova M, Soukupova J, et al. Relationship of pregnancy-associated plasma protein A to renal function and dialysis modalities. Kidney Blood Press Res 2004;27:88-95. (Pubitemid 38594560)
17. Kalousova M, Horejsi M, Fialova L, et al. Increased levels of pregnancy-associated plasma protein A are associated with mortality in hemodialysis patients: preliminary results. Blood Purif 2004;22:298-300. (Pubitemid 39177735)
18. Coskun A, Bicik Y, Duran S, et al. Pregnancy-associated plasma protein A in dialysis patients. Clin Chem Lab Med 2007;45:63-66. (Pubitemid 46155562)
19. Levey AS, Bosch JP, Lewis JB, Green T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
20. Bauvois B, Mothu N, Nguyen J, et al. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-β1 in patients with distinct types of glomerulonephritis. Nephrol Dial Transplant 2007;22:1115-22. (Pubitemid 46523426)
21. Chou FP, Chu SC, Cheng MC, et al. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 2002;35:383-8.
22. Peiskerova M, Kalousová M, Kratochvilova M, et al. Fibroblast growth factor 23 and Matrix metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res 2009;32:276-83.
23. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van Breemen C. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008;45:357-62. (Pubitemid 351793739)
24. Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and degradation. J Biol Chem 1996;271:15074-83. (Pubitemid 26194988)
25. Marti HP. Role of matrix metalloproteinases in the progression of renal lesions. Presse Med 2000;29:811-7. (Pubitemid 30230286)
26. Jerums G, Panagiotopoulos S, Tsalamandris C, Allen T, Gilbert RE, Comper WD. Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int 1997;52 [Suppl 63]:S87-S92. (Pubitemid 28020442)
27. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DCH. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537-45. (Pubitemid 27496471)
28. 1 and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001;87:240-8.
29. El Nahas AM. Pathway to renal fibrosis. Exp Nephrol 1995;3;71-5.
30. Steinmann-Niggli K, Yiswiler R, Küng M, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thy.1 nephritis. J Am Soc Nephrol 1998;9:397-407.
31. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003;162:1937-49. (Pubitemid 36613051)
32. Chang HR, Kuo WH, Hsieh YS, et al. Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients. Transpl Res 2008;151:217-23.
33. Büyükbabani N, Droz D. Distribution of the extracellular matrix components in human glomerular lesions. J Pathol 1994;172(2):199-207. (Pubitemid 24098672)
34. Fang Z, He F, Chen S, Sun X, Thu Y, Zhang C. Albumin modulates the production of matrix metalloproteinases-2 and -9 in podocytes. J Huazhong Univ Sci Technolog Med Sci. 2009;29(6):710-4.
35. Barrett AJ. α2-Macroglobulin. Methods Enzymol 1981;80:737-54.
36. Beaudeux JL, Burc L, Imbert-Bismut F, et al. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003;23:7-10.
37. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant. 2000;15:650-8. (Pubitemid 30242983)
38. Davies M, Thomas GJ, Martin J, Lovett DH. The purification and characterization of a glomerular basement membrane degrading neutral proteinase from rat mesangial cells. Biochem J 1988;251:419-25.
39. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinase 2. Cancer Res 1996;56:2707-10.
40. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 2001;38:715-28. (Pubitemid 32983278)